SAMSUNG PHARM. Co., LTD. (001360.KS)
KRW 1603.0
(0.25%)
KRW 1603.0
(0.25%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 16.25 Billion KRW | 223.01% |
| 2022 | 5.03 Billion KRW | -52.57% |
| 2021 | 10.61 Billion KRW | -19.53% |
| 2020 | 13.18 Billion KRW | 7.19% |
| 2019 | 12.3 Billion KRW | 32.16% |
| 2018 | 9.3 Billion KRW | -12.03% |
| 2017 | 10.58 Billion KRW | -19.59% |
| 2016 | 13.16 Billion KRW | 35.98% |
| 2015 | 9.67 Billion KRW | 57.52% |
| 2014 | 6.14 Billion KRW | -8.32% |
| 2013 | 6.7 Billion KRW | -39.38% |
| 2012 | 11.05 Billion KRW | 27.09% |
| 2011 | 8.69 Billion KRW | 37.46% |
| 2010 | 6.32 Billion KRW | -21.46% |
| 2009 | 8.05 Billion KRW | 19.07% |
| 2008 | 6.76 Billion KRW | 14.19% |
| 2007 | 5.92 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 16.83 Billion KRW | 3.58% |
| 2024 Q2 | 17.8 Billion KRW | 5.71% |
| 2023 Q1 | 8.31 Billion KRW | 65.12% |
| 2023 Q4 | 16.25 Billion KRW | 12.89% |
| 2023 Q3 | 14.4 Billion KRW | 34.44% |
| 2023 FY | 16.25 Billion KRW | 223.01% |
| 2023 Q2 | 10.71 Billion KRW | 28.88% |
| 2022 Q3 | 8.13 Billion KRW | 33.38% |
| 2022 FY | 5.03 Billion KRW | -52.57% |
| 2022 Q4 | 5.03 Billion KRW | -38.1% |
| 2022 Q1 | 8.42 Billion KRW | -20.62% |
| 2022 Q2 | 6.09 Billion KRW | -27.63% |
| 2021 Q4 | 10.61 Billion KRW | -21.69% |
| 2021 Q3 | 13.55 Billion KRW | 24.12% |
| 2021 Q2 | 10.91 Billion KRW | -14.07% |
| 2021 Q1 | 12.7 Billion KRW | -3.65% |
| 2021 FY | 10.61 Billion KRW | -19.53% |
| 2020 Q3 | 13.88 Billion KRW | 4.21% |
| 2020 Q1 | 12.26 Billion KRW | 0.0% |
| 2020 Q2 | 13.31 Billion KRW | 8.58% |
| 2020 Q4 | 13.18 Billion KRW | -5.0% |
| 2020 FY | 13.18 Billion KRW | 7.19% |
| 2019 FY | 12.3 Billion KRW | 32.16% |
| 2019 Q1 | 9.93 Billion KRW | 6.69% |
| 2019 Q2 | 10.16 Billion KRW | 2.34% |
| 2019 Q3 | 12.02 Billion KRW | 18.28% |
| 2018 Q1 | 11.63 Billion KRW | 9.94% |
| 2018 Q4 | 9.3 Billion KRW | -30.17% |
| 2018 Q2 | 13.04 Billion KRW | 12.15% |
| 2018 FY | 9.3 Billion KRW | -12.03% |
| 2018 Q3 | 13.33 Billion KRW | 2.17% |
| 2017 FY | 10.58 Billion KRW | -19.59% |
| 2017 Q4 | 10.58 Billion KRW | -19.47% |
| 2017 Q3 | 13.14 Billion KRW | 6.1% |
| 2017 Q2 | 12.38 Billion KRW | -0.86% |
| 2017 Q1 | 12.49 Billion KRW | -5.07% |
| 2016 FY | 13.16 Billion KRW | 35.98% |
| 2016 Q4 | 13.16 Billion KRW | -10.1% |
| 2016 Q3 | 14.63 Billion KRW | 17.43% |
| 2016 Q2 | 12.46 Billion KRW | 15.71% |
| 2016 Q1 | 10.77 Billion KRW | 11.32% |
| 2015 Q2 | 9.35 Billion KRW | 0.0% |
| 2015 Q3 | 11.26 Billion KRW | 20.41% |
| 2015 Q4 | 9.67 Billion KRW | -14.06% |
| 2015 FY | 9.67 Billion KRW | 57.52% |
| 2014 FY | 6.14 Billion KRW | -8.32% |
| 2014 Q4 | 6.14 Billion KRW | 0.0% |
| 2014 Q1 | 6.64 Billion KRW | -0.87% |
| 2013 FY | 6.7 Billion KRW | -39.38% |
| 2013 Q4 | 6.7 Billion KRW | -42.1% |
| 2013 Q3 | 11.57 Billion KRW | -0.71% |
| 2013 Q2 | 11.65 Billion KRW | -0.19% |
| 2013 Q1 | 11.67 Billion KRW | 5.64% |
| 2012 Q1 | 10.51 Billion KRW | 20.84% |
| 2012 Q2 | 10.72 Billion KRW | 2.06% |
| 2012 Q3 | 10.94 Billion KRW | 2.02% |
| 2012 Q4 | 11.05 Billion KRW | 1.01% |
| 2012 FY | 11.05 Billion KRW | 27.09% |
| 2011 Q4 | 8.69 Billion KRW | 14.1% |
| 2011 Q2 | 7.88 Billion KRW | 13.03% |
| 2011 Q1 | 6.97 Billion KRW | 10.29% |
| 2011 Q3 | 7.62 Billion KRW | -3.36% |
| 2011 FY | 8.69 Billion KRW | 37.46% |
| 2010 Q2 | 8.13 Billion KRW | 1.56% |
| 2010 Q3 | 8.02 Billion KRW | -1.3% |
| 2010 Q4 | 6.32 Billion KRW | -21.18% |
| 2010 Q1 | 8 Billion KRW | -0.6% |
| 2010 FY | 6.32 Billion KRW | -21.46% |
| 2009 Q3 | 7.76 Billion KRW | 17.52% |
| 2009 Q1 | 6.3 Billion KRW | -6.83% |
| 2009 Q4 | 8.05 Billion KRW | 3.72% |
| 2009 Q2 | 6.61 Billion KRW | 4.84% |
| 2009 FY | 8.05 Billion KRW | 19.07% |
| 2008 Q2 | 6.91 Billion KRW | 7.1% |
| 2008 Q3 | 6.49 Billion KRW | -6.1% |
| 2008 Q4 | 6.76 Billion KRW | 4.22% |
| 2008 FY | 6.76 Billion KRW | 14.19% |
| 2008 Q1 | 6.45 Billion KRW | 8.95% |
| 2007 Q3 | 6.11 Billion KRW | -6.2% |
| 2007 FY | 5.92 Billion KRW | 0.0% |
| 2007 Q4 | 5.92 Billion KRW | -3.17% |
| 2007 Q1 | 5.53 Billion KRW | 0.0% |
| 2007 Q2 | 6.52 Billion KRW | 17.93% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 44.15 Billion KRW | 63.176% |
| Dong-A Socio Holdings Co., Ltd. | 117.85 Billion KRW | 86.204% |
| Ildong Holdings Co., Ltd. | 91.16 Billion KRW | 82.166% |
| HANDOK Inc. | 94.46 Billion KRW | 82.789% |
| Kukje Pharma Co., Ltd. | 21.24 Billion KRW | 23.464% |
| Yuhan Corporation | 284.75 Billion KRW | 94.29% |
| Dong-A ST Co., Ltd. | 116.31 Billion KRW | 86.022% |
| Hanmi Pharm. Co., Ltd. | 288.81 Billion KRW | 94.371% |
| Hanall Biopharma Co.,Ltd | 32.38 Billion KRW | 49.794% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | 73.659% |
| Dong Sung Bio Pharm.Co.,Ltd. | 19.47 Billion KRW | 16.524% |
| MYUNGMOON Pharm co.,Ltd | 30.28 Billion KRW | 46.306% |
| Hana Pharm Co., Ltd. | 48.34 Billion KRW | 66.371% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | 63.176% |
| Ilsung Pharmaceuticals Co., Ltd. | 31.24 Billion KRW | 47.957% |
| REYON Pharmaceutical Co., Ltd. | 35.17 Billion KRW | 53.78% |
| Aprogen pharmaceuticals,Inc. | 48.12 Billion KRW | 66.218% |
| JW Holdings Corporation | 147.58 Billion KRW | 88.984% |
| Ildong Pharmaceutical Co., Ltd. | 84.62 Billion KRW | 80.787% |
| Chong Kun Dang Pharmaceutical Corp. | 261.43 Billion KRW | 93.781% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 84.675% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | 69.848% |
| Hyundai Pharmaceutical Co., Ltd. | 26.99 Billion KRW | 39.778% |
| Samil Pharmaceutical Co.,Ltd | 32.51 Billion KRW | 49.991% |
| Jeil Pharmaceutical Co.,Ltd | 109.76 Billion KRW | 85.188% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | 63.176% |
| Kwang Dong Pharmaceutical Co., Ltd. | 188.64 Billion KRW | 91.381% |
| Daewoong pharmaceutical Co.,Ltd | 241.54 Billion KRW | 93.269% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 84.675% |
| Yuhan Corporation | 284.75 Billion KRW | 94.29% |
| Jeil Pharma Holdings Inc | 125.28 Billion KRW | 87.022% |
| Yungjin Pharm. Co., Ltd. | 61.98 Billion KRW | 73.771% |
| Suheung Co., Ltd. | 259.84 Billion KRW | 93.743% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 84.675% |
| Samjin Pharmaceuticals Co., Ltd. | 79.6 Billion KRW | 79.575% |
| Korea United Pharm Inc. | 49.14 Billion KRW | 66.915% |
| CKD Bio Corp. | 69.08 Billion KRW | 76.465% |
| Daewon Pharmaceutical Co., Ltd. | 105.07 Billion KRW | 84.527% |
| Dongwha Pharm.Co.,Ltd | 70.69 Billion KRW | 77.002% |
| Whan In Pharm Co.,Ltd. | 54.05 Billion KRW | 69.924% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | 69.848% |
| Chong Kun Dang Holdings Corp. | 194.76 Billion KRW | 91.652% |
| Boryung Corporation | 189.8 Billion KRW | 91.434% |
| Bukwang Pharmaceutical Co., Ltd. | 56.83 Billion KRW | 71.392% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | 73.659% |
| JW Lifescience Corporation | 23.39 Billion KRW | 30.514% |